Test-retest Reproducibility of Right Heart Parameters of Chamber Size and Function
TERRA
Test Retest Reproducibility of Right heArt Parameters by Echocardiography and Cardiac Magnetic Resonance (EACVI TERRA Study)
1 other identifier
observational
215
0 countries
N/A
Brief Summary
The reliability of advanced echocardiographic and cardiac magnetic resonance (CMR) parameters at repeated measurements is not fully clarified. Test-retest reliability of measurements is crucial for follow-up studies and for clinical monitoring of patients to detect a significant change in ventricular performance, as well as to assess the outcome of various therapies on the size and function of cardiac structures. For echocardiography, the variability of the measurement is more complex, as it depends both on acquisition and reading variability, but also closer to the real life setting than observer variability. Much more limited data exist on the test-retest reliability of right heart parameters, i.e. right ventricle (RV), right atrial (RA) and tricuspid annulus (TA) parameters than on their observer variability and than of the equivalent left-sided parameters. The primary aim of the study is to compare the test-retest reproducibility and agreement of advanced echocardiographic parameters of RV and RA size and function, and of tricuspid annulus (TA) size against the respective parameters obtained by conventional echocardiography and by CMR (where applicable).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 23, 2023
CompletedStudy Start
First participant enrolled
January 1, 2024
CompletedFirst Posted
Study publicly available on registry
January 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2024
CompletedJanuary 5, 2024
January 1, 2024
3 months
August 23, 2023
January 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Right ventricular ejection fraction test-retest reproducibility
Agreement and intraclass correlation of 2 sets of repeated measurements 20 minutes apart by echocardiography and CMR
Through study completion, an average of 6 months
Right ventricular longitudinal strain test-retest reproducibility
Agreement and intraclass correlation of 2 sets of repeated measurements 20 minutes by echocardiography and CMR
Through study completion, an average of 6 months
Right atrial volume test-retest reproducibility
Agreement and intraclass correlation of 2 sets of repeated measurements 20 minutes by echocardiography and CMR
Through study completion, an average of 6 months
Tricuspid annulus size test-retest reproducibility
Agreement and intraclass correlation of 2 sets of repeated measurements 20 minutes by echocardiography and CMR
Through study completion, an average of 6 months
Eligibility Criteria
Consecutive patients fulfilling the study enrolment criteria, with clinical indication to perform echocardiography and CMR study, with a relatively fair distribution of RV ejection fraction: normal (25%), mildly reduced (25%), moderately reduced (25%) and severely reduced (25%)
You may qualify if:
- Age over 18 years old
- Informed consent
You may not qualify if:
- Age \<18 years old
- Pregnancy/breast feeding
- Tricuspid valve repair/prosthesis
- Pacemaker or implantable cardiac defibrillator
- Complex congenital diseases (exceptions: bicuspid aortic valve, atrial septal defect, ventricular septal defect, corrected tetralogy of Fallot)
- Poor acoustic window
- Inability to acquire 3D datasets with at least 20 volumes/s
- Very irregular R-R interval
- Claustrophobia
- Acute conditions
- Hemodynamically instable patients
- Patients who do not provide consent for the study protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Istituto Auxologico Italianolead
- Centro Cardiologico Monzinocollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Gianluca Pontone
Centro Cardiologico Monzino
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 23, 2023
First Posted
January 5, 2024
Study Start
January 1, 2024
Primary Completion
April 1, 2024
Study Completion
September 1, 2024
Last Updated
January 5, 2024
Record last verified: 2024-01